JACKSON CENTER, PA / ACCESSWIRE / April 3, 2023 / Halberd Corporation (OTC PINK:HALB) on March 29th met with five representatives from the Centers for Disease Control and Prevention (CDC). The CDC discussed Halberd’s incredible success eradicating multiple strains of antibiotic resistant (AR) E. coli bacteria and deadly Candida auris samples previously provided by the CDC. Halberd participants presented the repeated success in eradicating these pathogens in the testing conducted at Youngstown State University (YSU) by a team led by Drs. Chester Cooper and W. Gregg Sturrus.
Dr. Cooper, Professor, Department of Chemical and Biological Sciences at YSU, led off the meeting recounting the type and number of strains of antibiotic resistant bacteria and fungi which the CDC previously provided and the process used to prepare the various strains and evaluate them after testing. Dr. Sturrus then described in detail Halberd’s test results and procedure for using a tuned laser to selectively eradicate target antigens during the hour-long meeting. This built on the results Dr. Sturrus outlined in a recent TEDTalk: https://www.youtube.com/results?search_query=gregg+sturrus
The CDC representatives, from various specialties, noted Halberd’s success, and committed to provide additional bacteria and fungi strains considered dangerous and highly antibiotic resistant. A follow-up meeting with the CDC is planned after testing on these additional pathogen strains.
The CDC representatives provided information to Halberd on recommended next steps and potential supplemental funding for Halberd’s pursuits.
William A. Hartman, Halberd’s Chairman, President & CEO commented, “Our meeting with the CDC was a tremendous success, with the initial measure being the fact that this group of learned PhD’s gave us a full hour of their precious time. Their reaction to our results, particularly as evidenced by the multiplicity and direction of questioning by these astute investigators, confirmed that we are on the right track to eliminating multiple strains of antibiotic resistant bacteria and fungi. They encouraged us to continue our in-process work towards developing a therapeutic application of Halberd’s technology. That next step will involve mdi, the company which we have engaged for assistance in interfacing with the FDA.”
Hartman continued, “We will contact the various government agencies suggested by the CDC representatives in order to expedite further and more rapid development of Halberd’s patented and patent-pending technologies as well as potential supplemental funding opportunities.”
About Youngstown State University
Youngstown State University is a public university in Youngstown, Ohio, and is composed of 5 undergraduate colleges. The University has over 150 undergraduate degree programs and 50 graduate degree programs serving over 12,000 students in studies up to the doctoral level. Beyond its current student body, the university has more than 125,000 alumni across the country and around the world.
About Halberd Corporation.
Halberd Corporation (OTC-PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Since its restructuring in April of 2020, Halberd has obtained exclusive worldwide rights to four issued patents and has filed twenty related provisional, PCT, or utility patent applications to enhance its value to its stockholders and to attract the interests of potential development partners.
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Company cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Company undertakes no obligation to revise these statements following the date of this news release.
SOURCE: Halberd Corporation